Sign up online today & collaborate
or click here to find out more
AbbVie’s aging rheumatoid arthritis drug Humira has been approved as the first EU treatment for the skin disease hidradenitis suppurativa (HS).
HS, which is also known as acne inversa, is a painful, chronic inflammatory skin disease characterised by recurrent, painful abscesses and nodules on the skin – typically around the armpits and groin, on the buttocks and under the breasts.
The European Comission approval is based on the PIONEER Phase III studies, which showed that patients given Humira (adalimumab) had greater reductions in the numbers of abscesses and inflammatory nodules than patients given placebo.For more click here